Valuation: Amplia Therapeutics Limited

Market Cap 61.6M 43.94M 38.07M 35.99M 32.67M 61.23M 4.21B 430M 166M 2.14B 165M 161M 6.81B P/E 2027 *
-5.22x
P/E 2028 * -17.1x
Enterprise Value 43.7M 31.17M 27.01M 25.53M 23.18M 43.44M 2.99B 305M 118M 1.52B 117M 114M 4.83B EV / Sales 2027 *
-
EV / Sales 2028 * 4.02x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 day+4.17%
1 week+4.17%
Current month-7.41%
1 month-19.35%
3 months+13.64%
6 months+11.11%
Current year-16.67%
1 week 0.12
Extreme 0.115
0.13
1 month 0.12
Extreme 0.115
0.16
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.28
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 2022-12-04
Director of Finance/CFO - 2021-09-30
Chief Tech/Sci/R&D Officer - 2025-05-11
Director TitleAgeSince
Director/Board Member 70 2015-09-01
Chairman - 2018-05-24
Chairman - 2026-06-29
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/25 Exercice

Chairman

750,000 0.1933%
9/8/25 Free

Founder

447,000 0.1152%
9/8/25 Exercice

Director

535,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%+4.17%-21.88%+48.81% 43.93M
+0.66%+1.83%+47.32%+97.63% 69.18B
-1.19%-1.92%+34.57%+73.08% 62B
+2.22%-4.83%-15.32%+360.65% 26.19B
+1.46%+2.25%+28.84%+13.76% 25.75B
-0.89%-2.34%-3.46%-15.24% 24.29B
+2.84%+3.61%+24.60%-17.13% 19.84B
0.00%-10.41%+171.96%+298.75% 15.65B
-0.57%-1.37%-4.53%+825.13% 13.88B
-0.39%-4.24%-9.86%+483.04% 14.09B
Average +0.83%-2.61%+25.23%+216.85% 27.09B
Weighted average by Cap. +0.33%-1.18%+31.94%+159.87%

Financials

2027 *2028 *
Net sales - 9.5M 6.78M 5.87M 5.55M 5.04M 9.44M 650M 66.26M 25.6M 330M 25.45M 24.89M 1.05B
Net income -11.6M -8.27M -7.17M -6.78M -6.15M -11.53M -794M -80.9M -31.26M -403M -31.08M -30.39M -1.28B -4.1M -2.92M -2.53M -2.4M -2.17M -4.08M -281M -28.6M -11.05M -142M -10.99M -10.74M -454M
Net Debt -17.9M -12.77M -11.06M -10.46M -9.49M -17.79M -1.22B -125M -48.24M -621M -47.96M -46.9M -1.98B -23.4M -16.69M -14.46M -13.67M -12.41M -23.26M -1.6B -163M -63.06M -812M -62.7M -61.31M -2.59B
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
26-09-16 A$0.1250 +4.17% 12,412
26-09-16 A$0.1200 0.00% 149,897
26-09-15 A$0.1200 0.00% 553,722
26-09-14 A$0.1200 0.00% 249,146
26-09-11 A$0.1200 0.00% 916,457
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1200AUD
Average target price
0.4200AUD
Spread / Average Target
+250.00%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!